Second COVID Wave? Analysis And Updated Investment Strategy

|
Includes: AMZN, COST, GDX, GILD, HD, IAU, IBB, KO, LOW, MSFT, NKE, NVDA, ORCL, PEP, QQQ, SPY, TLT, TSM, WEC, WMT
by: DoctoRx
This article is exclusive for subscribers.
DoctoRx
Special situations, growth at reasonable price, value, micro-cap
Summary

An imminent second COVID wave remains a serious threat, but it may be fully priced in by now.

There are both bad and good things happening, but what I see is the mass media focusing more on the negatives.

Analysis of hospitalization and mortality trends is presented; reasons for concern but also significant improvement in death rates is a positive.

Beyond a COVID second wave (or not), the SPY was at a high valuation when the recession hit; its recovery to $300 may be too sharp and steep.

Safety in safe income and reasonably-valued dominant companies that can grow in these difficult times are this retiree's choices for capital allocation.

First, a comment on COVID-19: safety first

The most important thing I can say is to be appropriately fearful of COVID-19 and the virus which causes it.

Th virus is bad news no matter whether